Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prelude Therapeutics (PRLD) Accumulated Expenses (2023 - 2026)

Prelude Therapeutics' Accumulated Expenses history spans 4 years, with the latest figure at $2.5 million for Q1 2026.

  • On a quarterly basis, Accumulated Expenses fell 77.58% to $2.5 million in Q1 2026 year-over-year; TTM through Mar 2026 was $2.5 million, a 77.58% decrease, with the full-year FY2025 number at $12.5 million, down 17.59% from a year prior.
  • Accumulated Expenses hit $2.5 million in Q1 2026 for Prelude Therapeutics, down from $12.5 million in the prior quarter.
  • Over the last five years, Accumulated Expenses for PRLD hit a ceiling of $15.8 million in Q4 2023 and a floor of $2.5 million in Q1 2026.
  • Historically, Accumulated Expenses has averaged $10.5 million across 4 years, with a median of $11.4 million in 2024.
  • Biggest five-year swings in Accumulated Expenses: rose 11.39% in 2025 and later crashed 77.58% in 2026.
  • Tracing PRLD's Accumulated Expenses over 4 years: stood at $15.8 million in 2023, then dropped by 3.55% to $15.2 million in 2024, then decreased by 17.59% to $12.5 million in 2025, then plummeted by 79.78% to $2.5 million in 2026.
  • Business Quant data shows Accumulated Expenses for PRLD at $2.5 million in Q1 2026, $12.5 million in Q4 2025, and $6.5 million in Q3 2025.